Author + information
International multicenter clinical research (PLATO) confirmed that ticagrelor as a new type drug with stronger antithrombotic effect, significantly reduced the cardiovascular mortality and improved the prognosis of patients. At the same time, ticagrelor did not increase the risk of bleeding. However, the patients with clopidogrel resistance was not excluded in the PLATO study. It is unclear that whether ticagrelor can improve the prognosis of patients with non-clopidogrel resistance. The aim is to solve the problem.
194 patients without clopidogrel resistance were recruited in our center. After successful PCI(Percutaneous Coronary Intervention), 104 patients switched clopidogrel to ticagrelor after informed consent, and others continued to apply clopidogrel, and they were followed-up for 3 months. MACE(Major Adverse Cardiovascular Events) and bleeding events were prospectively recorded.
The results showed a significant lower rate of MACE in ticagrelor group. We did not observe significant differences in major or secondary bleeding between two groups, although the incidence of slight bleeding was obviously higher in ticagrelor group.
Our analysis demonstrated that ticagrelor decreased the rate of MACE but not increased the fatal bleeding incidence in patients with non-clopidogrel resistance. If possible, it require larger studies to validate our findings.